Form 4: Ocular Therapeutix Director Charles M. Warden Granted Equity Awards

Ocular Therapeutix, Inc. Director Charles M. Warden was granted 14,000 restricted stock units and 44,000 stock options as part of his compensation, as disclosed in a recent SEC Form 4 filing.

Summary

• Charles M. Warden, a Director of Ocular Therapeutix, Inc. (OCUL), was granted 14,000 restricted stock units (RSUs) and 44,000 stock options on June 11, 2025.
• The RSUs were granted under the Company's 2021 Stock Incentive Plan, with each RSU representing a right to receive one share of the Company's common stock.
• Both the RSUs and stock options will vest 100% on the first anniversary of the grant date (June 11, 2026) or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date, contingent on Mr. Warden's continued service on the board.
• The stock options have an exercise price of $8.82 per share and an expiration date of June 10, 2035.
• Following these transactions, Mr. Warden beneficially owns 86,464 shares of common stock and 44,000 stock options.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates continued commitment from a director through equity grants, which aligns interests with shareholders. It's a routine compensation event, so not highly impactful on its own.

Positives

• The grant of equity awards aligns the interests of Director Charles M. Warden with those of shareholders, incentivizing long-term performance and value creation.
• The continued service condition for vesting encourages stability and commitment from the board member.

Future Outlook

The vesting schedule for the granted equity awards indicates a future commitment from Director Charles M. Warden to continued service on the board of Ocular Therapeutix, Inc. through at least June 11, 2026, or until the next annual meeting of stockholders.

Industry Context

This filing represents a routine compensation event for a director, common across publicly traded companies in the biotechnology and pharmaceutical sectors, aiming to align executive and board member incentives with long-term shareholder value.

Corporate Governance

Related Party Transactions

• The grant of 14,000 restricted stock units and 44,000 stock options to Charles M. Warden, a Director of Ocular Therapeutix, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with long-term shareholder value, potentially leading to more focused decision-making aimed at increasing stock price. The increase in outstanding shares upon vesting could lead to minor dilution, but this is typical for equity compensation plans.

Next Steps

• The restricted stock units and stock options granted to Charles M. Warden are scheduled to vest 100% on June 11, 2026, or earlier, immediately prior to the next annual meeting of stockholders, subject to his continued service.
• Charles M. Warden will continue to serve on the board of directors of Ocular Therapeutix, Inc.

Key Dates

Keywords

Ocular Therapeutix, OCUL, SEC Form 4, Insider Trading, Restricted Stock Units, Stock Options, Equity Grant, Director Compensation, Charles M. Warden, Executive Compensation, Corporate Governance